Autolus Therapeutics plc (NASDAQ:AUTL) is one of the small-cap stocks with potential to rise 1000 percent. Unlike many biotech companies that are still waiting for their first approved product, Autolus already has a treatment on the market. Its drug AUCATZYL, also known as obe-cel, is approved for adults with a hard-to-treat form of blood cancer called relapsed or refractory B-cell acute lymphoblastic leukemia. In its May 14 first-quarter update, Autolus reported $26.2 million in AUCATZYL net product revenue, up from $9.0 million a year earlier, and said the business reached positive gross margin for the first time.

Autolus also kept its 2026 AUCATZYL revenue guidance at $120 million to $135 million, compared with $74 million in 2025. The company is trying to expand obe-cel beyond its first approved use, with studies in pediatric ALL, lupus nephritis, and progressive multiple sclerosis. On May 21, Autolus said an ASCO abstract from the FELIX study showed a 59% overall remission rate and a 42.6-month median duration of response in patients whose cancer had spread outside the bone marrow, a difficult-to-treat subgroup. Autolus ended the first quarter with $229.4 million in cash, cash equivalents, and marketable securities, enough to fund operations into the fourth quarter of 2027.

Autolus Therapeutics plc (NASDAQ:AUTL) is a commercial-stage biopharmaceutical company developing programmed T-cell therapies for cancer and autoimmune diseases.

While we acknowledge the potential of AUTL as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy. 

Disclosure: None. Follow Insider Monkey on Google News.